• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 12, 2021 at 11:52: PM
via Sanofi and Johnson & Johnson are adding more fuel to their CD38 rivalry fire between Sarclisa and Darzalex in multiple myeloma. With approvals already in place as triplet therapies, the two companies are now touting early clinical wins for four-drug regimens.

article source
 

<



Similar threads

cafead
ASH: J&amp;J, Sanofi square off in newly diagnosed multiple myeloma
Replies
0
Views
90
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Sanofi eyes FDA filing as orphan blood drug hits late-phase goal
Replies
0
Views
168
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell...
Replies
0
Views
168
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Roche offers glimpse of Columvi-Polivy combo&#039;s early lymphoma data as phase 3...
Replies
0
Views
80
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: With high tumor response, AstraZeneca spinout Dizal explores FDA path and US partner...
Replies
0
Views
177
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote